{rfName}
GL

Indexed in

License and use

Icono OpenAccess

Citations

Altmetrics

Grant support

Funding was received from Sociedad Espanola de Nefrologia (SEN), Sociedad Madrilena de Nefrologia (SOMANE), Fundacion Renal Inigo Alvarez de Toledo (FRIAT), Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA_COR-CM; Instituto de Salud Carlos III (ISCIII) Fondo de investigacion Sanitaria/Fondo Europeo de Desarrollo regional ( FEDER) (PI20/00744, PI22/00469, PI22/00050, PI21/00251, PI23/00627), ERA-PerMed- JTC2022 (SPAREKID AC22/00027), SIGNAL (AC22/00028), RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union- NextGenerationEU, Mecanismo para la Recuperacion y la Resiliencia (MRR) and SPACKDc PMP21/00109, FEDER funds, COST Action PERMEDIK CA21165, supported by COST ( European Cooperation in Science and Technology) ; PREVENTCKD Consortium Project ID: 101101220 Programme: EU4H DG/Agency: HADEA. KitNewCare, Project ID: 101137054, Call: HORIZON-HLTH-2023- CARE-04, Programme: HORIZON. DG/Agency: HADEA. PICKED Project ID 101168626 HORIZON-MSCA-2023-DN-01-01 MSCA Doctoral Networks 2023. This paper is part of a Supplement that was financially supported by the ERA. The topic of this paper was also presented at the 61st ERA Congress, Stockholm & Virtual, May 23-26, 2024.

Analysis of institutional authors

Ortiz, AlbertoAuthorFernandez-Fernandez, BeatrizCorresponding Author

Share

December 2, 2024
Publications
>
Article
Sí

GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity

Publicated to:Clinical Kidney Journal. 17 (Suppl 2): 19-35 - 2024-11-22 17(Suppl 2), DOI: 10.1093/ckj/sfae296

Authors: Abasheva, Daria; Ortiz, Alberto; Fernandez-Fernandez, Beatriz

Affiliations

IIS Fdn Jimenez Diaz UAM, Dept Nephrol & Hypertens, Madrid, Spain - Author
RICORS2040, Madrid, Spain - Author
Univ Autonoma Madrid, Fac Med, Dept Med, Madrid, Spain - Author

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular-kidney-metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) >= 30 kg/m(2)] or with overweight (BMI >= 27 kg/m(2)) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others. Additionally, liraglutide and semaglutide are approved to reduce CVD risk in patients with CVD and T2DM. Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD (FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity (SELECT trial). Thus, nephrologists should consider prescribing GLP-1 RAs to improve metabolic control, reduce CVD risk or improve kidney outcomes in three scenarios: patients with overweight and a related comorbid condition such as hypertension, dyslipidaemia or CVD, patients with obesity and patients with T2DM. This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health.

Keywords

Body-mass indexCardiovascular outcomesChronic kidney diseaseDouble-blindGlucagon-like peptide-1Glucagon-like peptide-1 (glp-1) receptor agonistsHypertensionLiraglutideManagemenObesityOnce-weekly cagrilintideOral semaglutideOverweighOverweightType-2Weight

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Kidney Journal due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 18/126, thus managing to position itself as a Q1 (Primer Cuartil), in the category Urology & Nephrology.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-03:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 30.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 21 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 23.65.
  • The number of mentions on the social network X (formerly Twitter): 38 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Abasheva, Daria) and Last Author (FERNANDEZ FERNANDEZ, BEATRIZ).

the author responsible for correspondence tasks has been FERNANDEZ FERNANDEZ, BEATRIZ.